Skip to content

Arcus Biosciences

US · RCUS #2467 by market cap Listed 2018
15.62 -0.16 -1.01%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:39

Price chart

Pre-market 16.06 +1.77%
After-hours 15.50 -0.77%
31.5715.6215.622026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on RCUS?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -36.8% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 9.3% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Operating margin -156.3% Better than 6%
Net margin -142.9% Better than 6%
Return on equity -63.3% Better than 8%
Return on invested capital -59.9% Better than 5%
Momentum D

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -48.5% Better than 6%
6-month return -33.3% Better than 16%
12-month return (ex latest month) -15.9% Better than 18%
Distance below 52-week high 50.8% Better than 18%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 4.4x Better than 83%
Debt to assets 9.8% Better than 70%
Interest coverage -43.1x Better than 8%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 83.3% Better than 63%
Upside to average target 166.6% Better than 92%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -10.38%
1M -34.23%
3M -47.09%
6M -34.20%
YTD -34.45%
1Y -26.42%
3Y +11.89%
5Y -67.15%

Key statistics

Price & volume

Prev close
15.78
Open
15.66
Day range
15.56 - 16.66
Avg price
15.80
Volume
1.67M
Turnover
26.45M
Amplitude
6.97%
52-week range
15.56 - 31.74

Valuation

P/E
-4.75
P/E (TTM)
-4.29
P/B
6.28
EPS
-3.29
Net profit
-473.73M
Net assets
357.96M

Share structure

Market cap
2.25B
Float cap
1.67B
Shares out
143.99M
Float shares
107.19M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2018-03-15
52-week range 0% of range
15.56 31.74

50.8% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-6.95M net over the window

Short interest

Shares short
13.18M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Arcus Biosciences (RCUS)?

Arcus Biosciences last traded at 15.62. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Arcus Biosciences's market cap?

About 2.25B.

What is the P/E ratio of Arcus Biosciences?

The trailing twelve-month P/E is -4.29, below its own 5-year average of 1.59 — in the middle of its historical range (46.25% percentile). See the Valuation tab for the full history.

Does Arcus Biosciences pay a dividend?

Arcus Biosciences does not currently pay a regular dividend.

Is Arcus Biosciences a buy according to analysts?

The consensus of 12 analysts is a Buy rating, with an average 12-month price target of 41.64, which implies 166.6% upside from the current price. This is not investment advice.

What is Arcus Biosciences's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Arcus Biosciences a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:39:06 · For reference only, not investment advice and not tailored to your situation.

Arcus Biosciences discussion 0 comments

Add a comment